Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - NRAP||cholangiocarcinoma||predicted - sensitive||Infigratinib||Case Reports/Case Series||Actionable||In a clinical case study, treatment with Truseltiq (infigratinib) resulted in stable disease for seven months in a patient with cholangiocarcinoma harboring an FGFR2-NRAP fusion (PMID: 34250419).||34250419|